CorMedix Q2 2026 net income rises 31.1% to $26 million; revenue more than doubled to $101.9 million
Reuters2026/08/13 11:33- CorMedix posted Q2 2026 consolidated revenue of USD 101.9 million, up 156.57% from a year earlier.
- Net income rose to USD 26 million; diluted EPS slipped to USD 0.29.
- Adjusted EBITDA (non-GAAP) climbed to USD 58.7 million from USD 22.4 million.
- DefenCath net revenue was USD 66.1 million; the acquired Melinta portfolio added USD 35.8 million.
- FY 2026 consolidated revenue guidance held at USD 325-345 million; adjusted EBITDA (non-GAAP) outlook raised to USD 125-140 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
